EGRX - Eagle Pharmaceuticals

-

$undefined

N/A

(N/A)

Eagle Pharmaceuticals NASDAQ:EGRX Eagle Pharmaceuticals Inc. is a fully integrated pharmaceutical company with research and development, clinical, manufacturing and commercial expertise. Eagle is committed to developing innovative medicines that result in meaningful improvements in patients' lives. Eagle's commercialized products include RYANODEX®, BENDEKA®, BELRAPZO®, and its oncology and CNS/metabolic critical care pipeline includes product candidates with the potential to address underserved therapeutic areas across multiple disease states.

Location: 50 Tice Blvd Ste 315, New Jersey, 07677-7637, US | Website: www.eagleus.com | Industry: Pharmaceutical Preparation Manufacturing | Sector: Manufacturing


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

66.19M

Cash

15.35M

Avg Qtr Burn

-2.33M

Short % of Float

4.18%

Insider Ownership

12.02%

Institutional Own.

78.81%

Qtr Updated

06/30/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date

Approved

Quarterly sales

Belrapzo (Bendamustine hydrochloride injection) Details
CLL (Chronic Lymphocytic Leukemia) and NHL (non-Hodgkins lymphoma)

Approved

Quarterly sales

Vasopressin Details
Vasodilary shock

Approved

Quarterly sales

Approved

Quarterly sales

Phase 3

Update

Phase 2/3

Data readout

Landiolol Details
Supraventricular tachycardia

Failed

Discontinued